Market Place
Sourcing Support
MaxCyte Celebrates 25 Years of Cell Engineering Innovation
13 Nov 2024 //
GLOBENEWSWIRE
MaxCyte Reports Q3 2024 Financials & Updates 2024 Guidance
06 Nov 2024 //
GLOBENEWSWIRE
MaxCyte Reports Q3 2024 Financials & Updates Guidance
06 Nov 2024 //
GLOBENEWSWIRE
MaxCyte to Participate in Two Upcoming Investor Conferences
31 Oct 2024 //
GLOBENEWSWIRE
MaxCyte Appoints Cynthia Collins to its Board of Directors
15 Oct 2024 //
GLOBENEWSWIRE
MaxCyte to Report Third Quarter 2024 Financial Results on Nov 6, 2024
11 Oct 2024 //
GLOBENEWSWIRE
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
10 Oct 2024 //
GLOBENEWSWIRE
MaxCyte Signs Platform License With Kamau For Cell Therapy Development
16 Sep 2024 //
GLOBENEWSWIRE
MaxCyte To Participate In Craig-Hallum Bioprocessing Conference
05 Sep 2024 //
GLOBENEWSWIRE
MaxCyte Reports Q2 2024 Results, Updates Full Year Guidance
06 Aug 2024 //
GLOBENEWSWIRE
MaxCyte Reports Q2 2024 Results And Updates Full Year Guidance
06 Aug 2024 //
GLOBENEWSWIRE
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
09 Jul 2024 //
GLOBENEWSWIRE
Porton Advanced Introduces MaxCyte ExPERT GTx Flow Electroporation Instrument
25 Jun 2024 //
PR NEWSWIRE
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
29 May 2024 //
GLOBENEWSWIRE
MaxCyte, Legend Bio Partner To Accelerate Cell Therapies
22 May 2024 //
GLOBENEWSWIRE
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
06 May 2024 //
GLOBENEWSWIRE
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
10 Apr 2024 //
GLOBENEWSWIRE
MaxCyte Signs Strategic Platform License with Be Biopharma
02 Apr 2024 //
GLOBENEWSWIRE
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
04 Mar 2024 //
GLOBENEWSWIRE
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results
09 Feb 2024 //
GLOBENEWSWIRE
MaxCyte and Wugen Sign Strategic Platform License
30 Jan 2024 //
GLOBENEWSWIRE
MaxCyte Signs Strategic Platform License with Imugene
23 Jan 2024 //
GLOBENEWSWIRE
MaxCyte Announces Preliminary Unaudited Fourth Quarter Financial Results
08 Jan 2024 //
GLOBENEWSWIRE
MaxCyte and Lion TCR form Partnership
03 Jan 2024 //
GLOBENEWSWIRE
MaxCyte Confirms Appointment of Maher Masoud as President, CEO and Director
02 Jan 2024 //
GLOBENEWSWIRE
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
11 Dec 2023 //
GLOBENEWSWIRE
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
16 Nov 2023 //
GLOBENEWSWIRE
MaxCyte Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
MaxCyte to Participate in Two Upcoming Investor Conferences
06 Nov 2023 //
GLOBENEWSWIRE
BioAtla to Participate in the Jefferies London Healthcare Conference
06 Nov 2023 //
GLOBENEWSWIRE
MaxCyte Announces Preliminary Third Quarter 2023 Revenue
04 Oct 2023 //
GLOBENEWSWIRE
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
06 Sep 2023 //
GLOBENEWSWIRE
MaxCyte to Participate in Baird Global Healthcare Conference
05 Sep 2023 //
GLOBENEWSWIRE
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
MaxCyte Signs Strategic Platform License with Prime Medicine
01 Aug 2023 //
GLOBENEWSWIRE
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
13 Jul 2023 //
GLOBENEWSWIRE
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License
10 Jul 2023 //
GLOBENEWSWIRE
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
06 Jul 2023 //
GLOBENEWSWIRE
MaxCyte to Participate in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
MaxCyte Reports 1Q 2023 Financial Results and Updates Full Year 2023 Guidance
10 May 2023 //
GLOBENEWSWIRE
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
12 Apr 2023 //
GLOBENEWSWIRE
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
27 Mar 2023 //
GLOBENEWSWIRE
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
MaxCyte Establishes New Scientific Advisory Board
08 Mar 2023 //
GLOBENEWSWIRE
MaxCyte Announces Fourth Quarter and Full Year 2022 Revenue Results
06 Mar 2023 //
GLOBENEWSWIRE
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results
01 Feb 2023 //
GLOBENEWSWIRE
MaxCyte Signs Strategic Platform License with Catamaran Bio t
03 Jan 2023 //
GLOBENEWSWIRE
MaxCyte Signs Strategic Platform License with Curamys Cell & Gene Therapies
04 Dec 2022 //
GLOBENEWSWIRE
MaxCyte Signs Strategic Platform License with Vertex Pharma to Advance CRISPR
29 Sep 2022 //
BIOSPACE
MaxCyte Signs Strategic Platform License with Vertex to Advance CRISPR/Cas9
28 Sep 2022 //
GLOBENEWSWIRE
MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare
07 Sep 2022 //
GLOBENEWSWIRE
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
10 Aug 2022 //
GLOBENEWSWIRE
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
15 Jul 2022 //
GLOBENEWSWIRE
MaxCyte Signs Platform License with LG Chem for Allogeneic CAR-T Programs
12 Jul 2022 //
GLOBENEWSWIRE
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 May 2022 //
GLOBENEWSWIRE
MaxCyte to Participate in Upcoming Investor Conferences
03 May 2022 //
GLOBENEWSWIRE
MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022
20 Apr 2022 //
GLOBENEWSWIRE
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Apr 2022 //
GLOBENEWSWIRE
MaxCyte Appoints Ron Holtz as Interim CFO, Announces Prelim Q1 2022 Revenue
12 Apr 2022 //
GLOBENEWSWIRE
